Axxess Pharma, Inc. to Sign Exclusive License Agreement to Market and Distribute FDA Approved Prescription Cough and Cold Capsule in Canada and Middle East
Published: Jul 12, 2010
ONTARIO, CA--(Marketwire - July 12, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they will be signing an exclusive license agreement to manufacture and distribute a unique FDA approved high potency cough and cold capsule. The exclusive license agreement will be signed within 2 weeks.
This capsule is currently being sold by physicians, pharmacists and specialists in the United States. Pending final approval from Health Canada, the high potency capsule will be sold under the Axxess Pharma name in Canada and the Middle East. The prescription cough and cold market currently generates over $2 billion in annual sales worldwide.
"Our latest prescription cough and cold capsule is anticipated to generate strong global sales for our company. Customers and patients will no longer need to carry bottles of cough and cold medicine. The unique capsule is easy to carry; currently FDA approved and is soon to be approved by Health Canada. We are now in discussion to expand the FDA approved prescription capsule into Africa," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973) 351-3868 or visit the company website directly: http://www.axxesspharma.com.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
Taylor Capitol, Inc.